Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Cancer Discov. 2012 Aug;2(8):679-84. doi: 10.1158/2159-8290.CD-12-0221. Epub 2012 Jul 27.
The p220 BRCA1 tumor suppressor protein has been implicated in multiple biochemical and biologic functions since its molecular cloning 18 years ago. Here, we discuss those functions most relevant for its tumor-suppressing activities with an emphasis on new findings. In particular, this review focuses on what is known of the activities of those BRCA1-binding partners that have tumor suppressor functions, on the reversion of mutant BRCA1 alleles concomitant with therapy resistance, on insights gained from studies of BRCA1 structure-function relationships, recent findings from animal models, and the potential role of BRCA1 in some nonhereditary tumors. From this information, a more detailed and refined picture of BRCA1 tumor suppression is beginning to emerge. Although key mysteries remain--such as why BRCA1 tumor suppression is focused on carcinomas of the breast and ovary--the pace of discovery is increasing.
BRCA1 functions as a clinically important classical tumor suppressor in hereditary breast and ovarian cancer; here, we review progress in understanding how BRCA1 operates to suppress tumor formation.
自 18 年前分子克隆以来,p220 BRCA1 肿瘤抑制蛋白已涉及多种生化和生物学功能。在这里,我们讨论了与肿瘤抑制活性最相关的那些功能,重点是新发现。特别是,本综述重点关注具有肿瘤抑制功能的 BRCA1 结合伴侣的活性、治疗耐药性时突变 BRCA1 等位基因的逆转、BRCA1 结构-功能关系研究的新发现、来自动物模型的最新发现以及 BRCA1 在某些非遗传性肿瘤中的潜在作用。根据这些信息,BRCA1 肿瘤抑制的更详细和精确的图片开始出现。尽管仍然存在关键的谜团,例如为什么 BRCA1 肿瘤抑制主要集中在乳腺癌和卵巢癌,但发现的速度正在加快。
BRCA1 作为遗传性乳腺癌和卵巢癌的重要临床经典肿瘤抑制因子;在这里,我们综述了理解 BRCA1 如何发挥作用抑制肿瘤形成的进展。